Latest article
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
LIVE QUOTE
Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine)
Scheduled to Initiate During the Second Half of This Year
ATLANTA, GA - April 15, 2026 (NEWMEDIAWIRE)...
Danger Will Robinson: the NIPAH virus with a 40-75% Death Rate.
Report: Nipah Virus Vaccine: Need, Development Landscape, and $3 Billion Market Opportunity
Report: Nipah Virus Vaccine: Need, Development Landscape, and $3 Billion Market Opportunity
Click to...
Report: AI Powered Review on GeoVax (GOVX) $1.15
In our view, a research report is designed to gather information on publicly traded companies from press releases, management presentations (including power points), SEC...
